Last reviewed · How we verify
NCT06712524
Effect of Different Surgical Approaches of Granulomatous Mastitis
NA trial testing Breast-conserving plastic surgery in Breast-conserving Plastic Surgery in 240 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Hubei Cancer Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 240 |
| Start date | 1 November 2024 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Breast-conserving plastic surgery
- Traditional breast surgery
Conditions studied
- Breast-conserving Plastic Surgery — all drugs for Breast-conserving Plastic Surgery →
- Granulomatous Mastitis — all drugs for Granulomatous Mastitis →
Sponsor
Hubei Cancer Hospital
Who can join
18 and older, female only, with Breast-conserving Plastic Surgery or Granulomatous Mastitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study was to prospectively investigate the effects of different surgical approaches on the recurrence rate and aesthetic outcome of patients with granulomatous mastitis. The patients were divided into traditional surgery group and plastic surgery group.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06712524
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Hubei Cancer Hospital trials
Trials by the same sponsor.
- NCT07188857 — Study on the Relationship Between Opioid Drugs and the Therapeutic Efficacy of Immunotherapy · not yet recruiting
- NCT06402435 — SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer · Phase 2 · recruiting
- NCT06401005 — SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC) · Phase 2 · recruiting
- NCT06714084 — CNCMT：a Multi-center, Prospective, Single-arm Study · NA · enrolling by invitation
- NCT06037733 — Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06712524 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hubei Cancer Hospital
- Last refreshed: 2 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06712524.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing